We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
B-Raf mutation and papillary thyroid carcinoma patients (Review).
- Authors
LIXIN JIANG; HAIDICHU; HAITAO ZHENG
- Abstract
Thyroid carcinoma is the most prevalent endocrine neoplasm globally. In the majority of thyroid carcinoma cases, a positive prognosis is predicted following administration of the appropriate treatment. A wide range of genetic alterations present in thyroid carcinoma exert their oncogenic actions partially through the activation of the mitogen-activated protein kinase pathway, with the B-Raf mutation in particular being focused on by experts for decades. The B-Raf gene has numerous mutations, however, V600E presents with the highest frequency. It is believed that the existence of the V600E mutation may demonstrate an association with the clinicopath-ological characteristics of patients, however, inconsistencies remain in the literature. A number of explanatory theories have been presented in order to resolve these discrepancies. Recently, it has been suggested that the V600E mutation may function as a target in a novel approach that may aid the diagnosis and prognosis of thyroid carcinoma, with a number of vying methods put forward to that effect. The current review aims to assist researchers in further understanding the possible association between B-Raf mutations and thyroid carcinoma.
- Subjects
THYROID cancer diagnosis; DISEASE prevalence; GENETIC mutation; ENDOCRINE gland tumors; MITOGEN-activated protein kinases
- Publication
Oncology Letters, 2016, Vol 11, Issue 4, p2699
- ISSN
1792-1074
- Publication type
Article
- DOI
10.3892/ol.2016.4298